| Filed On | Filing |
|---|---|
| 16 Nov 2026 | S-3 |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach |
| 16 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Regulation FD Disclosure
CORPORATE R&D AND KOL EVENT ACRIVON’S NEW I&I PROGRAMS DIFFERENTIATED ASSETS IDENTIFIED WITH PROPRIETARY AP3 PLATFORM NOVEMBER 10, 2026 Exhibit 99.1 |
| 06 Nov 2026 |
8-K: Other Events
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB |
| 26 Oct 2026 |
Form 4: Miller Mary, Chief Legal Officer
Sold 513 shares ($944) |
| 07 Oct 2026 |
Form 4: Miller Mary, Chief Legal Officer
Sold 294 shares ($585) |
| 02 Sep 2026 |
Form 4: Levin Michaela, Chief Business Officer
Received 30,000 shares as a grant or award · Granted 130,000 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 3: Levin Michaela, Chief Business Officer
No securities owned |
| 27 Aug 2026 |
Form 4: Blume-Jensen Peter, Director and 1 other
Sold 14,036 shares ($31K) |
| 25 Aug 2026 | 144 |
| 20 Aug 2026 |
Form 4: Peterson Katharine, Chief Accounting Officer
Sold 101 shares ($203) |
| 20 Aug 2026 |
Form 4: Miller Mary, Chief Legal Officer
Sold 185 shares ($372) |
| 20 Aug 2026 |
Form 4: Gamelin Erick, Chief Development Officer
Sold 400 shares ($804) |
| 20 Aug 2026 |
Form 4: Devroe Eric, Chief Operating Officer
Sold 604 shares ($1.21K) |
| 20 Aug 2026 |
Form 4: Blume-Jensen Peter, Director and 1 other
Sold 1,713 shares ($3.44K) |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | S-8 |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 |
| 12 Aug 2026 | 10-Q |
Loading...